LB Pharmaceuticals

A clinical-stage biopharmaceutical company on a mission to introduce a first-in-class antipsychotic for patients in the U.S. with neuropsychiatric conditions.

[LB Pharmaceuticals @lb_pharma]

We recently gathered as a team in New York. The opportunity to connect in person strengthened collaboration across our teams and reinforced the shared commitment behind the work we do advancing novel therapies for neuropsychiatric disorders. Learn more: https://t.co/7tpnoLYTDK

[LB Pharmaceuticals @lb_pharma]

We will participate in two upcoming investor conferences, where we’ll join industry leaders, investors, and peers to discuss our work advancing LB-102 as a potential new treatment for neuropsychiatric disorders. Details below and in our press release: https://t.co/xUpJ86MTzT

[LB Pharmaceuticals @lb_pharma]

Next up in our #LBBold series: Kathy Dorsey, Senior Director, Clinical Operations, who helps drive our clinical programs. To Kathy, being bold means acknowledging challenges and choosing to approach them as opportunities to learn and grow. Learn more: https://t.co/A9x2sYgDOq

[LB Pharmaceuticals @lb_pharma]

Our trials would not be possible without the patients, carepartners, and healthcare professionals who participate. On #ClinicalTrialsDay, we thank them for their commitment to advancing neuropsychiatric research. Learn more about #CTD2026: https://t.co/xNqmbe4mVU

[LB Pharmaceuticals @lb_pharma]

Don’t miss us at #ASCP2026, as we’ll be engaging with key opinion leaders and peers in neuropsyciatric drug development. Our team is looking forward to connecting with the community and contributing to discussions on advancing innovative therapies for neuropsychiatric conditions.

[LB Pharmaceuticals @lb_pharma]

We are proud to mark #MentalHealthMonth as part of a community working towards #MoreGoodDaysTogether and reflection on what supports mental well being. Learn more from @MentalHealthAm’s #MHM action guide: https://t.co/ayEnAtVjeH

[LB Pharmaceuticals @lb_pharma]

Our CEO, Heather Turner, will participate in a panel at the Convergence Forum alongside fellow industry leaders discussing their past experiences navigating bold biotech exits. Learn more about the event: https://t.co/4hSwlEREhI

[LB Pharmaceuticals @lb_pharma]

LB Pharma will be attending @SOBP’s #SOBP2026 to hear from top neuropsychiatry researchers and opinion leaders. We look forward to exchanging insights, and discussing our progress advancing LB-102, our investigational treatment for neuropsychiatric disorders.

[LB Pharmaceuticals @lb_pharma]

We are pleased to share that the results from NOVA-1, the Phase 2 trial which evaluated our investigational treatment LB-102 in #schizophrenia, are now published in @JAMAPsych. Read more: https://t.co/V7XnESpwzX

[LB Pharmaceuticals @lb_pharma]

Next up in our #LBBold series: Rezi Zawadzki, VP, Biometrics, who drives data-informed decisions across our programs. Motivated by the need for better mental health solutions, Rezi brings purpose to advancing LB-102. Learn more about our team: https://t.co/nvgqw5UCzp

[LB Pharmaceuticals @lb_pharma]

At #SIRS2026, we shared data from NOVA-1, the Phase 2 trial for our investigational therapy LB-102 in #Schizophrenia that underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia. Read more: https://t.co/7Xcb0WnPT9 $LBRX

[LB Pharmaceuticals @lb_pharma]

We have initiated NOVA-2, a pivotal Phase 3 trial of LB-102, once-daily, oral investigational small molecule being advanced as a potential first benzamide in the U.S. for the treatment of #Schizophrenia & other neuropsychiatric disorders. Learn more: https://t.co/PX3x5vkO8X $LBRX

[LB Pharmaceuticals @lb_pharma]

We’re looking forward to hosting a satellite symposium at the 2026 Annual Congress of @SIRSGlobal (#SIRS2026). Learn more about the conference: https://t.co/uhkqo0IFVr

[LB Pharmaceuticals @lb_pharma]

Excited to announce that Robert Lenz, M.D., Ph.D., has joined our Board of Directors. His neuroscience R&D leadership will help guide the clinical advancement of LB-102 in #Schizophrenia, #BipolarDepression & adjunctive #MajorDepressiveDisorder. More here: https://t.co/xSU3pusfr5

[LB Pharmaceuticals @lb_pharma]

Members of our leadership team will participate in the following investor events in March:
💡 Investival Showcase USA on March 10
🤝 Leerink Partners Global Healthcare Conference on March 11
🧠 Stifel 2026 Virtual CNS Forum on March 17

Details here: https://t.co/WjZK2ybYL8 $LBRX

[LB Pharmaceuticals @lb_pharma]

On International Day of Women and Girls in Science, we recognize the women of LB Pharma who represent 65% of our team and advance science with inclusive leadership and diverse perspectives. Learn more about #IDWGIS: https://t.co/lK5A42pYM4
#WomenInScience #EveryVoiceinScience

[LB Pharmaceuticals @lb_pharma]

With new funding secured, we intend to explore the potential of our investigational oral small molecule LB-102 as an adjunctive treatment for major depressive disorder in a Phase 2 trial. Learn more: https://t.co/NZjAp6MWgr $LBRX

[LB Pharmaceuticals @lb_pharma]

Bipolar disorder affects an estimated 2.8% of Americans and remains a significant burden. We are advancing LB-102, an investigational therapy for #BipolarDepression, in a recently initiated Phase 2 trial. Learn more: https://t.co/s28AUVLYEi

[LB Pharmaceuticals @lb_pharma]

Bold innovation requires purpose-driven people. In our new #LBBold series, we'll highlight the talented minds behind LB Pharma. Our Senior Director of Corporate Administration, Lauren Stipp, plays an important role in our success. Learn about our team: https://t.co/A9x2sYgDOq

[LB Pharmaceuticals @lb_pharma]

We have initiated ILLUMINATE-1, a Phase 2 trial evaluating our investigational oral small molecule, LB-102, in #BipolarDepression. This is an important step in advancing the development program for LB-102 to include mood disorders. Read more: https://t.co/4lVpNtRied $LBRX